TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23820196

Group type: EXPERIMENTAL
Intervention: Text with personalized video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text with video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text only
Number of subjects: 0
Study: 20549633

Group type: EXPERIMENTAL
Intervention: BDE mixture DE‐71 at doses of 0.5, 5, and 25 mg kg(‐1) body weight/day for 21 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDE mixture DE‐71
Number of subjects: 0
Study: 19473546

Group type: EXPERIMENTAL
Intervention: Tai chi intervention (2 sessions/week for 8 weeks, then 1 session/week for 2 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Wait-list control (usual health care practices)
Number of subjects: 160
Study: 17241416

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX-B) at doses ranging from 250 to 3,000 U
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 15111142

Group type: EXPERIMENTAL
Intervention: Autotransfusion (n = 98) receiving autotransfused washed blood from intraoperative cell salvage and postoperative mediastinal fluid cell salvage.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (n = 102) receiving stored homologous blood only after coronary artery bypass surgery.
Number of subjects: 200
Study: 11583861

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 795
Study: 9780640

Group type: EXPERIMENTAL
Intervention: Fasterzip
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 20
Study: 8067556

Group type: EXPERIMENTAL
Intervention: Topical EMLA cream applied to the skin of the flank overlying the kidney 90 min prior to the ESWL procedure.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo cream applied to the skin of the flank overlying the kidney 90 min prior to the ESWL procedure.
Number of subjects: 59
Study: 2898363

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg day-1
Number of subjects: 2276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2276
Study: 30138930

Group type: EXPERIMENTAL
Intervention: M-bar connector
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AP-bar connector
Number of subjects: 17

Group type: COMPARATOR
Intervention: No connector
Number of subjects: 17
Study: 27402556

Group type: EXPERIMENTAL
Intervention: Exercise + Alagebrium
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise + Placebo
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sedentary + Alagebrium
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sedentary + Placebo
Number of subjects: 62
Study: 25262259

Group type: EXPERIMENTAL
Intervention: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: EC-ASA 325 mg
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: PA32540
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1049
Study: 22835615

Group type: EXPERIMENTAL
Intervention: Nocturnal CPAP (8-10 cmH(2)O)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham treatment (0-2 cmH(2)O)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of CPAP vs Sham
Number of subjects: 25
Study: 19945509

Group type: EXPERIMENTAL
Intervention: bromazepam 3mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: bromazepam 6mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 18284414

Group type: EXPERIMENTAL
Intervention: Fluid intake decreased by 25% for 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluid intake increased by 25%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluid intake increased by 50%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluid intake decreased by 25%
Number of subjects: 24
Study: 15937581

Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg
Number of subjects: 70
Study: 12865387

Group type: EXPERIMENTAL
Intervention: Yogurt with added probiotic microorganisms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 24
Study: 10700778

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 1.0)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normocapnia (FIO2 0.21)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypocapnia (FIO2 0.21)
Number of subjects: 10
Study: 8881845

Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 1942470

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (1.34 micrograms/kg per d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 0
Study: 7199331

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microgram kg‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midazolam, fentanyl, and nitrous oxide
Number of subjects: 99
Study: 30807426

Group type: EXPERIMENTAL
Intervention: UI‐ELM intervention (35 students)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No intervention (control group, 20 students)
Number of subjects: 83

Group type: COMPARATOR
Intervention: UroGyn exposure (28 students)
Number of subjects: 83
Study: 27314596

Group type: EXPERIMENTAL
Intervention: i-gel®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce (AO)TM
Number of subjects: 60
Study: 27821836

Group type: COMPARATOR
Intervention: General anesthesia alone (Group G)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: GEA with 1.0% lidocaine (Group L1.0)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: GEA with 1.5% lidocaine (Group L1.5)
Number of subjects: 177
Study: 24102416

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg orally each day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg orally each day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg orally each day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Aggregate pre‐eclampsia
Number of subjects: 63
Study: 23610075

Group type: EXPERIMENTAL
Intervention: 70 mg epicatechin from apple extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 140 mg epicatechin from apple extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70 mg epicatechin from apple puree
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20831709

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (200,000 IU megadose)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 73
Study: 17552881

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells from untreated patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells from treated patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells with tetanus toxoid in untreated patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells with tetanus toxoid in treated patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells (both treated and untreated patients)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte proliferation in treated and untreated patients
Number of subjects: 5
Study: 15919731

Group type: EXPERIMENTAL
Intervention: Baseline BRS in IBS patients (7.9 +/- 5.4 ms/mmHg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Mild visceral stimulation (15 mmHg)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intense visceral stimulation (35 mmHg)
Number of subjects: 123
Study: 14526208

Group type: EXPERIMENTAL
Intervention: Educational intervention program
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Educational intervention program and Standard care (control group)
Number of subjects: 326
Study: 10390384

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 33
Study: 8893678

Group type: EXPERIMENTAL
Intervention: 1.25 mg of estrone sulfate (E1S)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.2 mg of 17 alpha-dihydroequilin sulfate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of E1S and 17 alpha-dihydroequilin sulfate
Number of subjects: 21
Study: 8393589

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-containing regimen
Number of subjects: 0
Study: 3522832

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 107
Study: 30141228

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici (1 × 10^9 colony-forming units each strain)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici
Number of subjects: 209
Study: 27977392

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study: 25496294

Group type: EXPERIMENTAL
Intervention: BVM biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 0
Study: 24114515

Group type: EXPERIMENTAL
Intervention: Hybrid medial approach (HMA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Completely medial approach (CMA)
Number of subjects: 99
Study: 22413151

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 19388617

Group type: EXPERIMENTAL
Intervention: Locking compression plate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonlocking plate
Number of subjects: 64
Study: 17156397

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study: 15854088

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy)
Number of subjects: 100
Study: 11975938

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln (beta-hydroxy-beta-methylbutyrate 3 g/d, L-arginine 14 g/d, L-glutamine 14 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (isonitrogenous mixture of nonessential amino acids)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 9873962

Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg rocuronium
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 450 micrograms/kg rocuronium
Number of subjects: 85
Study: 8712393

Group type: EXPERIMENTAL
Intervention: Combination of 0.2% isoflurane and 30% nitrous oxide in oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of 0.4% isoflurane and 30% nitrous oxide in oxygen
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2% isoflurane in oxygen
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.4% isoflurane in oxygen
Number of subjects: 10

Group type: COMPARATOR
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 10

Group type: COMPARATOR
Intervention: 100% oxygen-placebo
Number of subjects: 10
Study: 2066595

Group type: EXPERIMENTAL
Intervention: HR 0.5 g group (0.5 g X 2/day of CPR)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HR 1.0 g group (1.0 g X 2/day of CPR)
Number of subjects: 121

Group type: COMPARATOR
Intervention: CAZ group (1.0 g X 2/day of CAZ)
Number of subjects: 121
Study: 6843050

Group type: EXPERIMENTAL
Intervention: Aminophylline (Phyllotemp ret., 2 X 225 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight, i.v.)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31027457

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 413

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 413
Study: 29900704

Group type: EXPERIMENTAL
Intervention: Pixel-based second harmonic generation (SHG) polarization microscopy analyses
Number of subjects: 0
Study: 26739339

Group type: EXPERIMENTAL
Intervention: Home-based cognitive behavioral program (7 sessions: 3 home visits and 4 telephone contacts)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Home-based cognitive behavioral program
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 389
Study: 24858870

Group type: EXPERIMENTAL
Intervention: Patient Activation Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 22067410

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg three times a day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19104200

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 148) received a 1-hour training on information technology use, a CD-ROM on cancer, and a list of reputable cancer-related websites.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (n = 102) received usual care.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Women (part of the intervention group)
Number of subjects: 250
Study: 17584826

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel administration
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cumulative docetaxel doses and number of chemotherapy cycles
Number of subjects: 84
Study: 15516162

Group type: EXPERIMENTAL
Intervention: Early lip repair at median age 4 days (IQR = 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late lip repair at median age 104 days (IQR = 57)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal comparison infants
Number of subjects: 0
Study: 12207094

Group type: EXPERIMENTAL
Intervention: Low-salt diet (2 g NaCl/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-salt diet (20-23 g)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low-salt diet (2 g NaCl/day) after high-salt diet
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma ADMA level >/=3 microM
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Duration of dialysis treatment
Number of subjects: 75
Study: 9815203

Group type: EXPERIMENTAL
Intervention: MEDI‐493 (15 mg/kg intravenous infusion)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: MEDI‐493 and Placebo
Number of subjects: 35
Study: 7660443

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Mefloquine/sulfadoxine/pyrimethamine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 115
Study: 1892302

Group type: EXPERIMENTAL
Intervention: MK-571 (1,500, 86, or 28 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-571 (28 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-571 (277 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6684935

Group type: EXPERIMENTAL
Intervention: Bemetizide 1, 5, 10, 20, 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 0
Study: 30714500

Group type: EXPERIMENTAL
Intervention: Cochlear™ Nucleus® 7 Sound Processor (SP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Direct wireless streaming from an Apple® smartphone to the SP
Number of subjects: 37

Group type: COMPARATOR
Intervention: Previous generation SP
Number of subjects: 37
Study: 29524664

Group type: EXPERIMENTAL
Intervention: Cavity shave margins excision or re-excision of positive margins; specific details on dosage and duration not available.
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Younger patient age (under 60 years); specific details on dosage and duration not available.
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: High-grade ductal carcinoma in situ; specific details on dosage and duration not available.
Number of subjects: 235
Study: 27565996

Group type: EXPERIMENTAL
Intervention: Briefing on the recommendations for an unexpected difficult airway prior to induction of anaesthesia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Web-based cognitive aid with an emergency manual page containing the identical algorithm
Number of subjects: 19
Study: 24406256

Group type: EXPERIMENTAL
Intervention: Organo-silane product 1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Organo-silane product 2
Number of subjects: 9

Group type: COMPARATOR
Intervention: Quaternary ammonium disinfectant
Number of subjects: 9
Study: 21564271

Group type: EXPERIMENTAL
Intervention: ST(2), wax solvent (Dewaks, Faber Kimya & Ilaç, Turkey)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ST(3), boiling water followed by conditioning with methyl methacrylate (MMA) monomer (Meliodent, Bayer Dental, Germany)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ST(4), boiling water followed by wax solvent agent and finally MMA monomer application
Number of subjects: 120

Group type: COMPARATOR
Intervention: ST(1), no treatment applied (control)
Number of subjects: 120
Study: 19653481

Group type: EXPERIMENTAL
Intervention: Evidence accumulation model for conflict detection performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence accumulation models
Number of subjects: 0
Study: 17257471

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 440

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Absence of comorbid substance abuse
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Positive relationship with clinical staff (ROMI item)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Fulfillment of life goals (ROMI item)
Number of subjects: 440
Study: 15069045

Group type: COMPARATOR
Intervention: 21 or more ejaculations per month
Number of subjects: 29342

Group type: COMPARATOR
Intervention: High ejaculation frequency
Number of subjects: 29342

Group type: EXPERIMENTAL
Intervention: Ejaculation frequency
Number of subjects: 29342
Study: 12472855

Group type: EXPERIMENTAL
Intervention: Stabilization flat occlusal splint for night use (n = 21)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No splint (n = 16)
Number of subjects: 37
Study: 9799978

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia without prophylactic antiemetic treatment
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia
Number of subjects: 2220
Study: 7813605

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 6 mg benperidol (BPD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral liquid application of 6 mg benperidol (BPD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral tablet application of 6 mg benperidol (BPD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All applications of BPD (i.v., liquid, tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acute doses of BPD
Number of subjects: 12
Study: 2700321

Group type: EXPERIMENTAL
Intervention: 40 mg ketanserin dissolved in the mouth
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 4213977

Group type: EXPERIMENTAL
Intervention: Empiric treatment with carbenicillin and gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antibiotics in a prospective randomized trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic carbenicillin and oral gentamicin
Number of subjects: 0
Study: 30955978

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (case group)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 167
Study: 28525305

Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 452
Study: 25264764

Group type: EXPERIMENTAL
Intervention: Standard-view arm
Number of subjects: 5
Study: 23187956

Group type: EXPERIMENTAL
Intervention: Soybean protein supplement (40g, 89.3 mg isoflavones)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk protein supplement (40g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complex carbohydrate placebo (40g)
Number of subjects: 0
Study: 21592351

Group type: EXPERIMENTAL
Intervention: GWL (Group-based behavioral weight loss program)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: SWA-alone (SenseWear™ Armband alone)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: GWL+SWA (Group-based behavioral weight loss program plus SenseWear™ Armband)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard Care (self-directed weight loss program via an evidence-based weight loss manual)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: GWL
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: SWA-alone
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: GWL+SWA
Number of subjects: 197
Study: 19196674

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16530578

Group type: EXPERIMENTAL
Intervention: Azathioprine (1.0 mg/kg daily for heterozygous TPMT activity; 2.5 mg/kg daily for normal TPMT activity)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 63
Study: 12765849

Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation (DLPFC, 15 Hz, 110% motor threshold, 3000 stimuli/day for 10 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham rTMS stimulation (midline parieto-occipital, 90% of motor threshold)
Number of subjects: 25